Showing 5991-6000 of 7675 results for "".
- Zoryve from Arcutis Approved for Plaque Psoriasishttps://practicaldermatology.com/news/zoryve-from-arcutis-approved-for-plaque-psoriasis/2461282/FDA has approved the New Drug Application (NDA) for Zoryve (roflumilast) cream 0.3% from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The first and only topical phosphodiesterase-4 (PDE4) inhib
- The Foundation for Research and Education in Dermatology Welcomes Matt L. Leavitt, DO to Boardhttps://practicaldermatology.com/news/the-foundation-for-research-and-education-in-dermatology-welcomes-matt-l-leavitt-do-to-board/2461281/The Foundation for Research and Education in Dermatology (FRED), has named Matt L. Leavitt, DO as new member of its board. The Foundation says this decision marks the latest step in expanding its leadership at the executive and advisory levels. Dr. Leavitt is a board-certified derm
- Aesthetics Biomedical Adds to Leadership Team to Fuel Growth Trajectoryhttps://practicaldermatology.com/news/aesthetics-biomedical-adds-to-leadership-team-to-fuel-growth-trajectory/2461280/In an ongoing efforts to meet the increasing demand for its aesthetic products and distribution growth, Aesthetics Biomedical Inc. (ABM), is continuing to build its executive team with the recent hires of industry experts Derek Harmon as Vice President of U.S. Sales and Don Selvey, NMD, MS as Vic
- Incyte's Opzelura Adds Vitiligo Indicationhttps://practicaldermatology.com/news/incytes-opzelura-adds-vitiligo-indication/2461274/Opzelura™ (ruxolitinib) cream 1.5% from Incyte is now approved for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Opzelura is the first and only FDA-approved treatment for repigmentation in patients with vitiligo and the only topica
- Dermaliq Forms New Scientific and Medical Advisory Boardhttps://practicaldermatology.com/news/dermaliq-forms-new-scientific-and-medical-advisory-board/2461270/Dermaliq Therapeutics, Inc. has formed a Scientific and Medical Advisory Board. New members include Gordon Dow, Xavier Yon, Michael Kuligowski, MD, PhD, and R. Todd Plott, MD. The Advisory Board is composed of key clinical investigators and industry veterans in the field who suppor
- Novan's Berdazimer Gel Performs Well in Phase 3 for Molluscum: Studyhttps://practicaldermatology.com/news/novans-berdazimer-gel-performs-well-in-phase-3-for-molluscum-study/2461269/Berdazimer gel, 10.3% from Novan, Inc., significantly out-performed placebo for the treatment of molluscum, according to results of the B-SIMPLE 4 pivotal Phase 3 clinical study published in JAMA Dermatology</
- Dial Joins Forces with DonorsChoose and TeacherLists to Support Teachershttps://practicaldermatology.com/news/dial-joins-forces-with-donorschoose-and-teacherlists-to-supoort-teachers/2461264/Dial is doubling down on efforts to support teachers with a back-to-school marketing campaign. For the second year in a row, Dial has partnered with
- Systemic Inhibition of S100A9 May Reduce Severity of PsO, PsAhttps://practicaldermatology.com/news/systemic-inhibition-of-s100a9-may-reduce-severity-of-pso-psa/2461262/The severity of psoriasis and psoriatic arthritis can be reduced by inhibiting S100A9 systemically throughout the whole body rather than locally on the skin, according to a new study. By way of background, S100A9 activation in skin and immune cells has been identified as a risk factor f
- Sun Safety Day at Wrigley a Success for Sun Heroeshttps://practicaldermatology.com/news/sun-safety-day-at-wrigley-a-success-for-sun-heroes/2461261/As an extension of the Sun Heroes initiative, CeraVe's Sun Safety Day at Wrigley Field in partnership with Amy Brodsky, MD brought sun protection education to attendees as the Chicago Cubs hosted the Atlanta Braves. Dr. Brodsky founded
- SCUBE3 May Stimulate Hair Growthhttps://practicaldermatology.com/news/scube3-may-stimulate-hair-growth/2461254/University of California, Irvine-led researchers have discovered that a signaling molecule called SCUBE3 potently stimulates hair growth and may offer a therapeutic treatment for androgenetic alopecia, according to a study published in